Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

NCT02646748 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer (CRC)
Endometrial Cancer
Melanoma
Head and Neck Cancer
Lung Cancer
MMR-deficient Tumors
Breast Cancer
Pancreatic Cancer
Renal Cell Carcinoma (RCC)
Solid Tumors
UC (Urothelial Cancer)

Interventions

DRUG: Pembrolizumab
DRUG: itacitinib
DRUG: INCB050465

Sponsor

Incyte Corporation